Search bioRxiv⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.64898/2026.10.25.761728

CAR-macrophage immunotherapy targeting fibroblast-like synoviocytes ameliorates inflammatory and degenerative arthritis

Xu, Y.·Wang, Z.·Xie, D.·Zhang, L.·Yin, X.·Liang, C.
View original source ↗Export metadata ↓

Abstract

Rheumatoid arthritis (RA) is an inflammatory arthritis, whereas osteoarthritis (OA) is a degenerative joint disease. Despite their distinct etiologies, both are characterized by the pathogenic activation of fibroblast-like synoviocytes (FLS), which contribute to synovial hyperplasia, persistent inflammation, and cartilage destruction. Accordingly, pathogenic FLS represent an attractive therapeutic target for both RA and OA. Macrophages exhibit remarkable phenotypic plasticity, and interleukin-4 (IL-4) promotes an anti-inflammatory, tissue-reparative M2-like phenotype. Fibroblast activation protein (FAP) and nucleolin (NCL) are highly expressed on the surface of pathological FLS while exhibiting limited accessibility in normal tissues. Here, we developed two IL-4-armored, FLS-targeted chimeric antigen receptor macrophage (CAR-M) platforms directed against FAP or NCL, termed CAR-M2-FAP and CAR-M2-NCL, respectively. In vitro, both platforms enhanced FLS phagocytosis and promoted an M2-like transcriptional profile. Transcriptomic analysis further revealed enrichment of phagocytic, anti-inflammatory, and tissue-reparative programs. In a mouse model of RA, both CAR-M2 platforms attenuated arthritis severity, synovial hyperplasia, cartilage loss, and bone erosion. Similarly, in a mouse model of OA, they reduced synovitis, cartilage degeneration, and osteophyte formation. No overt acute toxicity was observed in either RA or OA mice following treatment with CAR-M2-FAP or CAR-M2-NCL. Collectively, the concordant therapeutic effects of CAR-M2-FAP and CAR-M2-NCL across RA and OA models provide preclinical proof of concept for FLS-targeted CAR-M2 as a potential therapeutic strategy for inflammatory and degenerative arthritis.

Explore related subjects

bioengineeringPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Xu, Y., Wang, Z., Xie, D., Zhang, L., Yin, X., Liang, C.. 2026-10-28. CAR-macrophage immunotherapy targeting fibroblast-like synoviocytes ameliorates inflammatory and degenerative arthritis. https://doi.org/10.64898/2026.10.25.761728

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Mesoscale Soft Robotics for Mechanically Perturbing and Functionally Monitoring Responses in Human Organoids

Human organoids represent promising models for studies of significance to the biology and medical communities. Of the existing approaches for monitoring organoids, none offers the ability to apply programmable mechanical forces while simultaneously recording multi-modal physiological responses, of relevance to phenomena spanning from traumatic brain injuries to cardiac rhythm disorders. Here, we present a mesoscale soft robotic organoid interface that enables programmable delivery of forces to organoids of diverse shapes, and to map electrophysiological activity and mechanical responses. The platform combines actuation elements with integrated sensors for quantitative measurement and control. Studies using this technology reveal that spheroidal cortical organoids exhibit distinct responses to mechanical trauma, including silencing, recovery, and changes in neuronal firing patterns. Additional experiments on cardiac ring tissues demonstrate that sustained stretching induces beat-to-beat rhythm variability and altered conduction. The results establish a framework for investigating force-triggered transitions between physiological and disease-like states in human tissue models.

bioengineering↗
bioRxiv2026

Few-shot regulatory sequence design with a genomic language model

A central challenge in generative biology is translating knowledge learned from natural sequences and experiments into designs with desired functions. In-context learning (ICL) is an emergent capability of large language models that allows them to adapt to new tasks from a few examples without additional training, enabling these models to become general-purpose learners. Here, we show that the genome language model, Evo 2, exhibits generative ICL in biological sequence design. Prompting with just tens of examples conditions Evo 2 to generate novel and diverse regulatory DNA sequences without any additional training. Mechanistic analysis suggests that genomic ICL may originate from induction, similar to phenomena observed in natural language. Reinforcement learning leveraging sequence-to-function models as experiment-derived rewards further strengthens ICL. We first validate this approach by generating enhancers that drive cell-type-specific gene expression in three human cell lines. Extending this approach in vivo, enhancers designed using human regulatory element data selectively label layer 5 extratelencephalic neurons in the mouse cortex with high specificity and stronger activity than existing enhancers. Our study provides evidence of emergent properties in genomic sequence models and introduces a promising approach for improving functional conditioning in generative biology.

bioengineering↗
bioRxiv2026

IOP-independent treatment for neurodegeneration in glaucoma using optimized ROS-scavenging microparticles for sustained release of erythropoietin

Glaucoma is a slow-progressing neurodegenerative disease of the optic projection to the brain and a leading cause of blindness worldwide. Current treatments are targeted towards lowering intraocular pressure (IOP), the only known, modifiable risk factor; however, this strategy is ineffective in many patients. An early hallmark of glaucomatous neurodegeneration is increased reactive oxygen species (ROS), representing an alternative opportunity for intervention to halt or slow disease progression. In this work, we optimize a ROS-scavenging copolymer, poly(propylene sulfide-co-ethylene sulfide) (PPSES), for formulation of size-controlled, stabilized, antioxidant microparticles (MPs) for sustained release of the protein erythropoietin (EPO). EPO promotes biological antioxidant defense via activation of NRF2-mediated transcription of antioxidant genes. This MP system overcomes the short half-life of EPO and leverages the combined benefits of bioactive EPO with long-lasting, inherently antioxidant PPSES MPs. The lead EPO-MP formulation preserves neurons in both mouse and non-human primate models of glaucoma through suppression of oxidative stress and optic nerve degeneration. EPO-loaded PPSES MPs represent a translationally relevant therapy for long-term management of glaucoma independent of IOP.

bioengineering↗